Better screening for hepatic steatosis in primary care
AI-generated hypothesis · Pre-publication · To be tested experimentally
Table of contents — full brief
- Hypothesis and mechanismCausal chain, key assumptions, residual unknowns
- State of the artVerified references and counter-evidence (DOIs)
- Falsifiable predictionsQuantitative bounds, statistical tests, H0
- Experimental protocolThree phases — in silico → minimal → full
- Impact analysisNovelty, residual gaps, available data
- Panel reviewFive personas + meta-review
Verified references
5 of 11 references- DOI: 10.1053/j.gastro.2021.07.049 ↗
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
2021 - DOI: 10.1002/hep4.1411 ↗
Impact of Implementing a “FIB‐4 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary Care
2019 - DOI: 10.1371/journal.pone.0147237 ↗
Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score
2016 - DOI: 10.9778/cmajo.20200009 ↗
Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.
2020 - DOI: 10.1016/S2468-1253(18)30077-3 ↗
Non-alcoholic fatty liver disease and the interface between primary and secondary care.
2018
+ 6 more references
Detailed panel scores
The protocol is thoughtfully structured in three phases, allowing for iterative validation and de-risking before a full-scale trial.
The hypothesis is well aligned with current guidelines and evidence supporting the use of FIB-4 in primary care for NAFLD risk stratification, as demonstrated by the cited literature.
Addresses a clinically important gap: primary care management of NAFLD is often suboptimal, and systematic risk stratification could improve care.
The global NAFLD/NASH market is expanding, with a prevalence of approximately 25% and a projected market size of $20–30 billion by 2025 for diagnostics and therapeutics; primary care constitutes a high-volume entry point.
Addresses a significant public health burden (NAFLD) with a pragmatic, scalable intervention in primary care, aligning with health systems strengthening priorities.
Receive the next SPORE hypotheses
Once or twice a month, in your inbox. No spam, one-click unsubscribe.
Your data stays private. No third-party sharing. GDPR-compliant.